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FACTORS ASSOCIATEDWITH RISK OF METABOLIC
SYNDROME FOR US FIRST GENERATION ADOLESCENTS
(AGES 12–17)
Sias S, Hufstader MA,White-Means S
University of Tennessee Health Science Center, Memphis,TN, USA
OBJECTIVE: To contrast the factors that are associated with
metabolic syndrome risk for ﬁrst generation adolescents and US
non-immigrant adolescents. METHODS: At risk is deﬁned as
having one or more of the following: elevated fasting glucose,
elevated SBP, elevated BMI, 75th percentile waist circumference,
or low HDL. Logistic regression and NHANES 2005–2006 data
were used to examine the impact on metabolic syndrome risks;
gender, ethnicity, length of residence, income, and number of
meals eaten outside the home per week. First generation Hispanic
and non-Hispanic adolescents are compared with adolescent
non-immigrants. A signiﬁcance level of 0.05 was used. Sample
sizes for Hispanic ﬁrst generation adolescents, non-Hispanic ﬁrst
generation adolescents, and non-immigrant adolescents are
1,076,059, 674,536, and 22,091,170 respectively. RESULTS:
About 71% of ﬁrst generation adolescent Hispanics, 67% for
non-Hispanic other ﬁrst generation adolescents, and 67% of
non-immigrant adolescents are at risk for metabolic syndrome.
Signiﬁcant predictors for risk among Hispanics are female
gender, longer time of residence in the United States, and low
familial income. For every one meal eaten outside the home risk
increases by 11%. For other non-Hispanics, the male gender is a
negative predictor along with low and middle familial income
levels. Length of residence in the United States and meals eaten
outside the home were not signiﬁcant predictors. Among the
non-immigrants, male gender is a negative predictor, while low
and middle income increase risk by 60% and 47% respectively.
Each meal eaten outside the home increases their risk by 3%.
CONCLUSION: These adolescents are at risk for acute cardio-
vascular endpoints, higher medical utilization and expenditure,
and lower quality of life. Interventions should focus on education
regarding healthy eating outside the home with limited resources.
A surprising result of this analysis is the high price of accultura-
tion for Hispanic ﬁrst generation adolescents in particular.
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RESIDUAL DYSLIPIDEMIA ON SIMVASTATIN: POPULATION
MODELING OF OPTIMAL LIPIDVALUE ACHIEVEMENTWITH
ADDED EXTENDED-RELEASE NIACINVERSUS EZETIMIBE
Stanek E1, Charland S2
1None,Thorofare, NJ, USA, 2School of Pharmacy, University of
Colorado,Winter Park, CO, USA
OBJECTIVE: To compare the population modeling effects of
simvastatin alone, simvastatin plus ezetimibe and simvastatin
plus extended-release niacin (ERN) on achievement of individual
and combined optimal lipid values in untreated managed care
patients with coronary heart disease (CHD) or risk equivalent
(CHD/RE). METHODS: Patients with a baseline lipid panel
between January 1, 2000-December 31, 2001, no concomitant
dyslipidemia therapy, continuous eligibility for 24 months, and
CHD or CHD/RE by diagnosis or procedure were analyzed from
a 2.1 million record managed care database (HealthCore, Inc.
Research Integrated Dataset). Patient-level lipids were assessed
for achievement of guideline-deﬁned optimal lipid values for
LDL-C (<100 mg/dL), HDL-C (>40 mg/dL men; >50 mg/dL
women), triglycerides (TG; <150 mg/dL), non-HDL-C (<130 mg/
dL), and combined LDL-C + HDL-C + TG at untreated baseline,
after simvastatin 40 mg, after simvastatin + ezetimibe 10 mg,
and after simvastatin + ERN 1 g and 2 g. Treatment effects were
modeled based on product labeling, assuming additivity for sim-
vastatin and ERN. Primary outcome measure was percentage of
patients with nonoptimal values. RESULTS: Analysis included
20,948 patients: 49% female, mean (SD) age 65  14 years,
hypertension 62%, diabetes 34%. At untreated baseline, nonop-
timal values occurred in 79% for LDL-C, 43% HDL-C, 42%
TG, 77% nonHDL-C, and 92% for combined lipids. After
modeled therapy, nonoptimal value frequencies were: simvastatin
LDL-C 34%, HDL-C 14%, TG 34%, nonHDL-C 36%, and
combined 69% (p < 0.05 vs baseline); simvastatin + ezetimibe
LDL-C 21%, HDL-C 23%, TG 32%, nonHDL-C 31%,
and combined 53% (p < 0.05 vs baseline, simvastatin);
simvastatin + ERN 1 g and 2 g LDL-C 25% and 18%, HDL-C
0.2% and 0%, TG 30% and 22%, nonHDL-C 20% and 10%,
and combined 46% and 36% [p < 0.05 vs baseline, simvastatin,
simvastatin + ezetimibe (p = NS for TG at 1 g dose)]. CONCLU-
SION: In this high-risk population, nonoptimal lipid values were
very prevalent and persisted after modeled simvastatin 40 mg.
Modeled simvastatin + ERN 1–2 g diminished residual dyslipi-
demia and nonoptimal lipid values more than simvastatin +
ezetimibe.
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OBJECTIVE: Co-morbidity indices based on drug utilization
have been used to predict costs of care. The original RxRisk
co-morbid disease index was based on United States (US)
National Drug Code (NDC) numbers, and as such, needed to be
updated at the NDC level for any change in manufacturer,
repackager, or generic status, or with the introduction of each
new molecular entity to the US market. The RxRisk-V was a
modiﬁcation of the original that used Veteran Affairs (VA) drug
codes rather than NDC numbers to assign co-morbidity status
for a set of diseases. Use of VA drug codes rather than NDCs
simpliﬁes the process of updating the tool. We undertook to
create a crosswalk between VA drug codes and FirstDataBank
(FDB) categories so the tool could be used with non-VA phar-
macy data. METHODS: We obtained SAS code and disease
category tables for the RxRisk-V. Clinical pharmacists reviewed
the RxRisk-V disease categories and created an algorithm for
mapping VA therapeutic categories to FDB speciﬁc drug thera-
peutic class categories. Pharmacists also updated disease catego-
ries to include drugs that would not have been updated in the
RxRisk-V due to new therapeutic categories introduced since
1999. Generic name, brand name, and route of administration
ﬁelds were used to specify which agents within each FDB thera-
peutic class were predictive of each RxRisk-V disease category.
The SAS code for the RxRisk-V was modiﬁed to crosswalk
between VA codes and non-VA pharmacy data. RESULTS: We
successfully applied the crosswalk to a cohort of 19,458 patients
from the RxAmerica database and generated co-morbidity
scores. CONCLUSION: Using the RxRisk-V enables investiga-
tors to apply an updated co-morbid disease severity index to VA
pharmacy data. We created a crosswalk to enable use with
non-VA pharmacy data. Future work is needed to validate the
tool with the crosswalk incorporated.
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